Omalizumab Evidence: Trial Results and Peer-Reviewed Publications

Hipa.ai Research · Source: PubMed & ClinicalTrials.gov / AACT · Last updated:

The clinical evidence base for Omalizumab comprises 232 peer-reviewed publications across 15 journals, 29 pivotal-trial primary-outcome rows reported to ClinicalTrials.gov, spanning indications including Asthma, Chronic Urticaria, Sinusitis, and Hypersensitivity. Most recent publication: Matching-adjusted indirect comparison analysis of omalizumab versus dupilumab in patients with chronic spontaneous urticaria., J Allergy Clin Immunol Glob, 2026.

Top peer-reviewed publications

Curated set of pivotal-trial result papers and recent publications in high-tier journals.

  1. Omalizumab for the Treatment of Multiple Food Allergies.
    Wood RA, Togias A, Sicherer SH, et al. · N Engl J Med · 2024
    PubMed: PMID 38407394 · NCT03881696 (OUtMATCH) · Peanut Hypersensitivity
  2. Double-Blind, Placebo-Controlled Study of E-B-FAHF-2 in Combination With Omalizumab-Facilitated Multiallergen Oral Immunotherapy.
    Wang J, Wood RA, Raymond S, et al. · J Allergy Clin Immunol Pract · 2023
    PubMed: PMID 37087097 · NCT06103656 (FAHF-2) · Food Hypersensitivity
  3. The basophil proteome in chronic spontaneous urticaria distinguishes responders to omalizumab from non-responders.
    Stitt JM, Dzieciatkowska M, Edwards MG, et al. · Clin Exp Allergy · 2019
    PubMed: PMID 29671921 · NCT01701583 · Chronic Urticaria
  4. Phase 2, randomized multi oral immunotherapy with omalizumab 'real life' study.
    Sindher SB, Kumar D, Cao S, et al. · Allergy · 2022
    PubMed: PMID 35014049 · NCT03181009 · Food Hypersensitivity
  5. The efficacy of omalizumab treatment in chronic spontaneous urticaria is associated with basophil phenotypes.
    Johal KJ, Chichester KL, Oliver ET, et al. · J Allergy Clin Immunol · 2021
    PubMed: PMID 33713769 · NCT03111628 · Chronic Urticaria
  6. Omalizumab for treatment of idiopathic angioedema.
    Goswamy VP, Lee KE, McKernan EM, et al. · Ann Allergy Asthma Immunol · 2022
    PubMed: PMID 35914662 · NCT02966314 · Angioedema
  7. Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials.
    Gevaert P, Omachi TA, Corren J, et al. · J Allergy Clin Immunol · 2021
    PubMed: PMID 32524991 · NCT05405478 · Nasal Polyps
  8. Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children.
    Busse WW, Morgan WJ, Gergen PJ, et al. · N Engl J Med · 2011
    PubMed: PMID 21410369 · NCT00377572 (ICATA) · Asthma

Primary-outcome results across pivotal trials

Per-arm reported values from Phase 2/3 and Phase 3 trials with results posted to ClinicalTrials.gov.

TrialIndicationPrimary endpointArmValue
NCT00079937AsthmaPercentage of Participants With at Least 1 Adverse Event
Baseline to end of the study (Week 68)
Omalizumab90.3 Percentage of participants
Placebo93.7 Percentage of participants
NCT00079937AsthmaRate of Clinically Significant Asthma Exacerbations Per Patient in the 24-week Fixed-dose Steroid Treatment Period
Baseline to end of the fixed-dose steroid treatment period (Week 24)
Omalizumab0.45 Exacerbations per patient per 24-weeks
Placebo0.64 Exacerbations per patient per 24-weeks
NCT00314574AsthmaRate of Asthma Exacerbations Over the 48 Week Treatment Period
48 weeks
Placebo0.88 exacerbation/patient-week
Xolair0.66 exacerbation/patient-week
NCT00396409—Daily Symptom Load
Recorded daily during the 2007 and 2008 pollen season
Depigoid + Omalizumab1.32 units on a scale (±1.74 Standard Deviation)
Depigoid + Omalizumab1.25 units on a scale (±0.99 Standard Deviation)
Depigoid + Placebo0.97 units on a scale (±1.02 Standard Deviation)
Depigoid + Placebo1.10 units on a scale (±0.99 Standard Deviation)
NCT00500539AsthmaThe Number of Participants With Confirmed Positive Human Antihuman Antibody (HAHA) Results at the End of the 16-week Follow-up Period
16 weeks after last dose
Follow-up Period0 participants
Follow-up Period0 participants
Follow-up Period0 participants
Follow-up Period0 participants
Follow-up Period0 participants
Follow-up Period0 participants
Follow-up Period0 participants
Follow-up Period0 participants
NCT01007149
NATAIR
AsthmaChange From Baseline in the Expression of FcεRI Receptors of Blood Basophils
Baseline and 16 weeks
Omalizumab-84.4 Percent change in MFI (±17.80 Standard Deviation)
Placebo27.7 Percent change in MFI (±87.90 Standard Deviation)
NCT01007149
NATAIR
AsthmaChange From Baseline in the Expression of FcεRI Receptors of Dendritic Cells
Baseline and 16 weeks
Omalizumab-56.7 Percent change in MFI (±19.74 Standard Deviation)
Placebo24.8 Percent change in MFI (±111.71 Standard Deviation)
NCT01202903AsthmaChange From Baseline in Mean Morning Peak Expiratory Flow (PEF) Following the 24-week Treatment Period
Baseline, 24 weeks
Omalizumab27.03 L/min (±20.865 Standard Error)
Placebo18.18 L/min (±21.086 Standard Error)
NCT01264939Chronic UrticariaPercentage of Participants With Adverse Events
Baseline to the end of study (up to 40 weeks)
Omalizumab 300 mg83.7 Percentage of participants
Placebo78.3 Percentage of participants
NCT01287117Chronic UrticariaChange From Baseline to Week 12 in the Weekly Itch Severity Score
Baseline to Week 12
Omalizumab 150 mg-6.66 Units on a scale (±6.28 Standard Deviation)
Omalizumab 300 mg-9.40 Units on a scale (±5.73 Standard Deviation)
Omalizumab 75 mg-6.46 Units on a scale (±6.14 Standard Deviation)
Placebo-3.63 Units on a scale (±5.22 Standard Deviation)
NCT01292473Chronic UrticariaChange From Baseline in the Weekly Itch Severity Score at Week 12
Baseline, Week 12
Omalizumab 150 mg-8.14 Units on a scale (±6.44 Standard Deviation)
Omalizumab 300 mg-9.77 Units on a scale (±5.95 Standard Deviation)
Omalizumab 75 mg-5.87 Units on a scale (±6.45 Standard Deviation)
Placebo-5.14 Units on a scale (±5.58 Standard Deviation)
NCT01723072
X-ACT
Chronic UrticariaMean Change From Baseline Using Chronic Urticaria Quality of Life Questionnaire (CU-Q2oL) Total Scores During the Study: Unadjusted Analysis and ANCOVA (LOCF) (FAS)
Baseline, 4, 12, 20, 28 and 36 weeks
Omalizumab-31.4 score (±23.7 Standard Deviation)
Omalizumab-32.1 score (±21.8 Standard Deviation)
Omalizumab-23.9 score (±23.0 Standard Deviation)
Omalizumab-35.1 score (±24.2 Standard Deviation)
Omalizumab-25.5 score (±21.3 Standard Deviation)
Placebo-14.7 score (±19.2 Standard Deviation)
Placebo-13.9 score (±17.7 Standard Deviation)
Placebo-16.2 score (±18.8 Standard Deviation)
Placebo-12.1 score (±20.3 Standard Deviation)
Placebo-6.4 score (±15.9 Standard Deviation)
NCT02161562
OPTIMA
Chronic UrticariaNumber of Participants Who Were Clinically Well-controlled (UAS7<=6) After the Initial Dosing Period, Relapsed (UAS7>=16) When Treatment Was Discontinued, and Who Achieved a UAS7 Score <=6 at the End of the Second Dosing Period (Retreatment A2 and B2)
Last 7 days of second dosing period, 44 weeks
All Retreatment (A2&B2)43 Participants
Retreatment (A2)10 Participants
Retreatment (B2)33 Participants
NCT02329223—Change From Baseline in the Weekly Itch Severity Score at Week 12
Baseline to Week 12
Omalizumab 150 mg-8.80 Units on a scale (±0.591 Standard Error)
Omalizumab 300 mg-10.22 Units on a scale (±0.571 Standard Error)
Placebo-6.51 Units on a scale (±0.581 Standard Error)
NCT03280537
POLYP 2
Nasal PolypsChange From Baseline in Average Daily Nasal Congestion Score (NCS) at Week 24
Baseline, Week 24 (Study Days 155 to 186)
Omalizumab-0.70 Score on a scale
Placebo-0.20 Score on a scale
NCT03280537
POLYP 2
Nasal PolypsChange From Baseline in Nasal Polyp Score (NPS) at Week 24
Baseline, Week 24
Omalizumab-0.90 Score on a scale
Placebo-0.31 Score on a scale
NCT03280550
POLYP 1
Nasal PolypsChange From Baseline in Average Daily Nasal Congestion Score (NCS) at Week 24
Baseline, Week 24 (Study Days 155 to 186)
Omalizumab-0.89 Score on a scale
Placebo-0.35 Score on a scale
NCT03280550
POLYP 1
Nasal PolypsChange From Baseline in Nasal Polyp Score (NPS) at Week 24
Baseline, Week 24
Omalizumab-1.08 Score on a scale
Placebo0.06 Score on a scale
NCT03328897Chronic UrticariaChange From Baseline of the Itch Severity Score (ISS7) Score After 12 Weeks of Treatment
Baseline, Week 12
Omalizumab 150mg-9.66 Score on a scale (±0.424 Standard Error)
Omalizumab 300mg-10.11 Score on a scale (±0.430 Standard Error)
Placebo-5.87 Score on a scale (±0.604 Standard Error)
NCT03369704Rhinitis, Allergic, SeasonalMean Nasal Symptom Score
Severe symptom period (from 23Feb2018 to 24March2018)
Omalizumab3.66 score (±0.151 Standard Error)
Placebo4.69 score (±0.144 Standard Error)
NCT03478930Nasal PolypsChange From Baseline in Average Daily Nasal Congestion Score (NCS)
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, and 76
Received Omalizumab in GA39688 or GA39855-0.39 Score on a scale
Received Omalizumab in GA39688 or GA39855-0.73 Score on a scale
Received Omalizumab in GA39688 or GA39855-0.81 Score on a scale
Received Omalizumab in GA39688 or GA39855-0.88 Score on a scale
Received Omalizumab in GA39688 or GA39855-0.85 Score on a scale
Received Omalizumab in GA39688 or GA39855-0.85 Score on a scale
Received Omalizumab in GA39688 or GA39855-0.88 Score on a scale
Received Omalizumab in GA39688 or GA39855-0.90 Score on a scale
Received Omalizumab in GA39688 or GA39855-0.98 Score on a scale
Received Omalizumab in GA39688 or GA39855-1.02 Score on a scale
Received Omalizumab in GA39688 or GA39855-1.04 Score on a scale
Received Omalizumab in GA39688 or GA39855-1.04 Score on a scale
Received Omalizumab in GA39688 or GA39855-1.12 Score on a scale
Received Omalizumab in GA39688 or GA39855-0.98 Score on a scale
Received Omalizumab in GA39688 or GA39855-0.88 Score on a scale
Received Omalizumab in GA39688 or GA39855-0.88 Score on a scale
Received Omalizumab in GA39688 or GA39855-0.78 Score on a scale
Received Omalizumab in GA39688 or GA39855-0.71 Score on a scale
Received Omalizumab in GA39688 or GA39855-0.65 Score on a scale
Received Placebo in GA39688 or GA39855-0.80 Score on a scale
Received Placebo in GA39688 or GA39855-0.61 Score on a scale
Received Placebo in GA39688 or GA39855-0.72 Score on a scale
Received Placebo in GA39688 or GA39855-0.74 Score on a scale
Received Placebo in GA39688 or GA39855-0.73 Score on a scale
Received Placebo in GA39688 or GA39855-0.89 Score on a scale
Received Placebo in GA39688 or GA39855-0.94 Score on a scale
Received Placebo in GA39688 or GA39855-0.99 Score on a scale
Received Placebo in GA39688 or GA39855-0.71 Score on a scale
Received Placebo in GA39688 or GA39855-0.17 Score on a scale
Received Placebo in GA39688 or GA39855-0.25 Score on a scale
Received Placebo in GA39688 or GA39855-0.31 Score on a scale
Received Placebo in GA39688 or GA39855-0.32 Score on a scale
Received Placebo in GA39688 or GA39855-0.34 Score on a scale
Received Placebo in GA39688 or GA39855-0.58 Score on a scale
Received Placebo in GA39688 or GA39855-0.56 Score on a scale
Received Placebo in GA39688 or GA39855-0.64 Score on a scale
Received Placebo in GA39688 or GA39855-0.63 Score on a scale
Received Placebo in GA39688 or GA39855-0.31 Score on a scale
NCT03478930Nasal PolypsChange From Baseline in Nasal Polyp Score (NPS)
Baseline, Weeks 4, 8, 16, 24, 36, 52, 64, and 76
Received Omalizumab in GA39688 or GA39855-0.85 Sore on a scale
Received Omalizumab in GA39688 or GA39855-1.06 Sore on a scale
Received Omalizumab in GA39688 or GA39855-1.09 Sore on a scale
Received Omalizumab in GA39688 or GA39855-1.01 Sore on a scale
Received Omalizumab in GA39688 or GA39855-1.09 Sore on a scale
Received Omalizumab in GA39688 or GA39855-1.31 Sore on a scale
Received Omalizumab in GA39688 or GA39855-0.85 Sore on a scale
Received Omalizumab in GA39688 or GA39855-0.54 Sore on a scale
Received Placebo in GA39688 or GA39855-0.17 Sore on a scale
Received Placebo in GA39688 or GA39855-0.48 Sore on a scale
Received Placebo in GA39688 or GA39855-0.40 Sore on a scale
Received Placebo in GA39688 or GA39855-0.97 Sore on a scale
Received Placebo in GA39688 or GA39855-0.83 Sore on a scale
Received Placebo in GA39688 or GA39855-0.19 Sore on a scale
Received Placebo in GA39688 or GA39855-0.17 Sore on a scale
Received Placebo in GA39688 or GA39855-0.26 Sore on a scale
NCT03478930Nasal PolypsPercentage of Participants With Adverse Events (AE) and Serious Adverse Events (SAE)
From Start to End (Weeks 24 to 52) of OLE Study
Received Omalizumab in GA39688 or GA3985543.5 Percentage of Participants
Received Omalizumab in GA39688 or GA398552.4 Percentage of Participants
Received Placebo in GA39688 or GA3985549.6 Percentage of Participants
Received Placebo in GA39688 or GA398554.8 Percentage of Participants
NCT03478930Nasal PolypsPercentage of Participants With Adverse Events Leading to Discontinuation of Omalizumab
From Start to End (Weeks 24 to 76) of OLE Study
Received Omalizumab in GA39688 or GA398550.0 Percentage of Participants
Received Placebo in GA39688 or GA398550.8 Percentage of Participants
NCT03580356Chronic UrticariaMean Change From Baseline in UAS7 at Week 12 (Multiple Imputation) of Adult Subjects
Baseline, Week 12
Ligelizumab 120 mg-20.312 Scores on a scale (±0.654 Standard Error)
Ligelizumab 72 mg-19.218 Scores on a scale (±0.651 Standard Error)
Omalizumab 300 mg-19.632 Scores on a scale (±0.652 Standard Error)
Placebo-9.221 Scores on a scale (±1.135 Standard Error)
NCT03580356Chronic UrticariaMean Change From Baseline in UAS7 at Week 12 (Observed Data) of Adolescent Subjects (FAS)
Baseline, Week 12
Ligelizumab 120 mg-24.83 scores on a scale (±12.640 Standard Deviation)
Ligelizumab 72 mg-14.92 scores on a scale (±13.479 Standard Deviation)
Omalizumab 300 mg-18.16 scores on a scale (±10.246 Standard Deviation)
Placebo-11.94 scores on a scale (±14.278 Standard Deviation)
NCT03580369Chronic UrticariaMean Change From Baseline in UAS7 at Week 12 (Multiple Imputation) of Adult Subjects
Baseline, Week 12
Ligelizumab 120 mg-19.330 Score (±0.660 Standard Error)
Ligelizumab 72 mg-19.368 Score (±0.668 Standard Error)
Omalizumab 300 mg-20.040 Score (±0.663 Standard Error)
Placebo-11.366 Score (±1.129 Standard Error)
NCT03580369Chronic UrticariaMean Change From Baseline in UAS7 at Week 12 (Observed Data) of Adolescent Subjects (FAS)
Baseline, Week 12
Ligelizumab 120 mg-14.64 Score (±14.662 Standard Deviation)
Ligelizumab 72 mg-17.39 Score (±13.070 Standard Deviation)
Omalizumab 300 mg-13.84 Score (±15.343 Standard Deviation)
Placebo-12.75 Score (±18.738 Standard Deviation)
NCT03881696
OUtMATCH
Peanut HypersensitivityNumber of Participants by Stage 1 Treatment Assignment, Omalizumab Versus Placebo, Who Successfully Consume a Single Dose of ≥600 mg of Peanut Protein Without Dose-Limiting Symptoms During the DBPCFC Conducted at the End of Treatment Stage 1
During the DBPCFC at the end of Stage 1: 16 to 20 weeks after Stage 1 treatment initiation
Omalizumab79 Participants
Omalizumab39 Participants
Placebo for Omalizumab4 Participants
Placebo for Omalizumab55 Participants

Publications by year

1976–2026: 232 publications.

1976
2
1977
1
1978
1
1985
2
1989
1
1990
1
1991
2
1992
1
1993
1
1994
2
1995
2
1996
4
1997
8
1998
4
1999
1
2000
4
2001
7
2002
7
2003
7
2004
9
2005
15
2006
10
2007
5
2009
4
2010
5
2011
12
2012
4
2013
5
2014
5
2015
4
2016
9
2017
9
2018
3
2019
10
2020
12
2021
17
2022
16
2023
4
2024
9
2025
5
2026
2

Publications by indication

Asthma (46)

  • Dupilumab versus omalizumab in patients with chronic rhinosinusitis with nasal polyps and coexisting asthma (EVEREST): a multicentre, randomised, double-blind, head-to-head phase 4 trial.
    Lancet Respir Med · 2025 · PMID 41033334 · NCT04998604
  • Allergen Immunotherapy for the Prevention and Treatment of Asthma.
    Clin Exp Allergy · 2025 · PMID 39363801 · NCT06027073
  • Efficacy and safety of a proposed omalizumab biosimilar compared to the reference product in the management of uncontrolled moderate-to-severe allergic asthma: a multicenter, phase III, randomized, double-blind, equivalency clinical trial.
    Front Immunol · 2024 · PMID 39136011 · NCT05813470
  • Does Comorbid Food Allergy Affect Response to Omalizumab in Patients with Asthma?
    J Asthma Allergy · 2024 · PMID 39309477 · NCT01922037
  • Effectiveness of omalizumab across different dosing regimens in patients with moderate-to-severe allergic asthma.
    Respir Med · 2024 · PMID 38253245 · NCT01922037

Chronic Urticaria (27)

  • Matching-adjusted indirect comparison analysis of omalizumab versus dupilumab in patients with chronic spontaneous urticaria.
    J Allergy Clin Immunol Glob · 2026 · PMID 41847564 · NCT01287117
  • EXtending Omalizumab Treatment Intervals in patients with Chronic spontaneous urticaria (EXOTIC): protocol of a multicentre, randomised, open-label, non-inferiority trial.
    BMJ Open · 2025 · PMID 39762098 · NCT05916937
  • Tezepelumab for the treatment of chronic spontaneous urticaria: Results of the phase 2b INCEPTION study.
    J Allergy Clin Immunol · 2025 · PMID 39956278 · NCT04833855
  • Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trials.
    Lancet · 2024 · PMID 38008109 · NCT03580369
  • Does angioedema in patients with chronic spontaneous urticaria impact response to omalizumab?
    World Allergy Organ J · 2024 · PMID 39193419 · NCT01292473

Sinusitis (24)

  • A randomized, double-blind, placebo-controlled trial of anti-IgE for chronic rhinosinusitis.
    Rhinology · 2010 · PMID 21038023 · NCT00117611
  • The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics.
    Eur Respir J · 2002 · PMID 11529281 · NCT00117611
  • Psychometric and clinimetric validity of the 20-Item Sino-Nasal Outcome Test (SNOT-20).
    Otolaryngol Head Neck Surg · 2002 · PMID 11821764 · NCT00117611
  • Allergic rhinitis as a risk factor for orbital complication of acute rhinosinusitis in children.
    Am J Rhinol · 2002 · PMID 11777246 · NCT00117611
  • Prevalence and relationship between allergic diseases and infectious diseases.
    J Microbiol Immunol Infect · 2001 · PMID 11321129 · NCT00117611

Hypersensitivity (18)

  • Omalizumab Dose-Related Efficacy in a Cohort of Children With Severe Food Allergy: OSAFA Observational Study.
    Allergy · 2026 · PMID 41555682 · NCT06316414
  • Omalizumab reduces anaphylactic reactions and allows food introduction in food-allergic in children with severe asthma: An observational study.
    Allergy · 2025 · PMID 39282750 · NCT06316414
  • New evidence in food allergies treatment.
    Curr Opin Allergy Clin Immunol · 2024 · PMID 38814736 · NCT03679676
  • Impact of Omalizumab on Food Allergy in Patients Treated for Asthma: A Real-Life Study.
    J Allergy Clin Immunol Pract · 2020 · PMID 30797778 · NCT06316414
  • Twelve-year follow-up of omalizumab therapy for anaphylaxis in 2 patients with systemic mastocytosis.
    J Allergy Clin Immunol Pract · 2020 · PMID 30149096 · NCT00890162

Rhinitis, Allergic (16)

  • Cat allergen-induced blood basophil reactivity in vitro predicts acute human nasal allergen challenge responses in vivo.
    Clin Exp Allergy · 2011 · PMID 21668817 · NCT00604786
  • Objective monitoring of nasal patency and nasal physiology in rhinitis.
    J Allergy Clin Immunol · 2007 · PMID 15746882 · NCT00604786
  • Omalizumab for asthma.
    N Engl J Med · 2006 · PMID 16790701 · NCT00604786
  • Nasal lavage fluid concentrations of eotaxin-1 (CCL11) in naturally occurring allergic rhinitis: relationship to disease activity, nasal luminal eosinophil influx, and plasma protein exudation.
    Clin Exp Allergy · 2006 · PMID 16120080 · NCT00604786
  • Safety and tolerability of omalizumab (Xolair), a recombinant humanized monoclonal anti-IgE antibody.
    Clin Rev Allergy Immunol · 2006 · PMID 16222082 · NCT00604786

Urticaria (12)

  • Impact of omalizumab on patient-reported outcomes in chronic idiopathic urticaria: Results from a randomized study (XTEND-CIU).
    J Allergy Clin Immunol Pract · 2020 · PMID 31034999 · NCT02392624
  • A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria.
    J Allergy Clin Immunol · 2011 · PMID 21762974 · NCT00130234
  • Omalizumab-induced reductions in mast cell Fce psilon RI expression and function.
    J Allergy Clin Immunol · 2004 · PMID 15356552 · NCT00130234
  • Quality of life and patients' satisfaction in chronic urticaria and respiratory allergy.
    Allergy · 2004 · PMID 12823121 · NCT00130234
  • Classification of anti-FcepsilonRI and anti-IgE autoantibodies in chronic idiopathic urticaria and correlation with disease severity.
    J Allergy Clin Immunol · 2002 · PMID 12209101 · NCT00130234

Publications by journal

Trial-results highlights

Clinical trials have investigated omalizumab for asthma. In NCT00079937, the rate of clinically significant asthma exacerbations per patient over 24 weeks was a mean of 0.45 exacerbations in the omalizumab arm, compared to a mean of 0.64 exacerbations in the placebo arm. Regarding adverse events in the same study, 90.3% of participants in the omalizumab arm experienced at least one adverse event, while 93.7% of participants in the placebo arm did. Another study, NCT00314574, reported an asthma exacerbation rate over 48 weeks of 0.66 exacerbation/patient-week for the Xolair arm and 0.88 exacerbation/patient-week for the placebo arm.

Further asthma studies explored other outcomes. In NCT01202903, the change from baseline in mean morning peak expiratory flow (PEF) after 24 weeks was 27.03 L/min for the omalizumab arm and 18.18 L/min for the placebo arm. NCT01007149 (NATAIR) examined changes in receptor expression; the omalizumab arm showed a mean -84.4% change in FcεRI receptors of blood basophils and a mean -56.7% change in FcεRI receptors of dendritic cells, while the placebo arm showed a mean 27.7% change for basophils and a mean 24.8% change for dendritic cells. A safety endpoint in NCT00500539 found 0 participants with confirmed positive human antihuman antibody (HAHA) results at the end of the 16-week follow-up period across all reported groups.

One study, NCT00396409, investigated daily symptom load during pollen season. The Depigoid + Omalizumab arm reported mean daily symptom loads of 1.32 units and 1.25 units on a scale, while the Depigoid + Placebo arm reported mean daily symptom loads of 0.97 units and 1.10 units on a scale.

All values are sourced from primary registry reporting; individual papers should be consulted for clinical decisions.

All Omalizumab publications (232)

2026 (2 papers)

  1. Matching-adjusted indirect comparison analysis of omalizumab versus dupilumab in patients with chronic spontaneous urticaria.
    Mosnaim G, Seetasith A, Holden M, et al. · J Allergy Clin Immunol Glob · 2026 · Derived
    PubMed: PMID 41847564 · NCT01287117 · Chronic Urticaria
  2. Omalizumab Dose-Related Efficacy in a Cohort of Children With Severe Food Allergy: OSAFA Observational Study.
    Arasi S, Bitetti C, Lo Scalzo L, et al. · Allergy · 2026 · Derived
    PubMed: PMID 41555682 · NCT06316414 (OSAFA) · Hypersensitivity

2025 (5 papers)

  1. EXtending Omalizumab Treatment Intervals in patients with Chronic spontaneous urticaria (EXOTIC): protocol of a multicentre, randomised, open-label, non-inferiority trial.
    Zhang DG, Sørensen JA, Ghazanfar MN, et al. · BMJ Open · 2025 · Derived
    PubMed: PMID 39762098 · NCT05916937 (EXOTIC) · Chronic Urticaria
  2. Dupilumab versus omalizumab in patients with chronic rhinosinusitis with nasal polyps and coexisting asthma (EVEREST): a multicentre, randomised, double-blind, head-to-head phase 4 trial.
    De Corso E, Canonica GW, Heffler E, et al. · Lancet Respir Med · 2025 · Derived
    PubMed: PMID 41033334 · NCT04998604 (EVEREST) · Asthma
  3. Allergen Immunotherapy for the Prevention and Treatment of Asthma.
    Batard T, Taillé C, Guilleminault L, et al. · Clin Exp Allergy · 2025 · Derived
    PubMed: PMID 39363801 · NCT06027073 (BSIPL) · Asthma
  4. Omalizumab reduces anaphylactic reactions and allows food introduction in food-allergic in children with severe asthma: An observational study.
    Arasi S, Cafarotti A, Galletta F, et al. · Allergy · 2025 · Derived
    PubMed: PMID 39282750 · NCT06316414 (OSAFA) · Hypersensitivity
  5. Tezepelumab for the treatment of chronic spontaneous urticaria: Results of the phase 2b INCEPTION study.
    McLaren J, Chon Y, Gorski KS, et al. · J Allergy Clin Immunol · 2025 · Background
    PubMed: PMID 39956278 · NCT04833855 (INCEPTION) · Chronic Urticaria

2024 (9 papers)

  1. Omalizumab for the Treatment of Multiple Food Allergies.
    Wood RA, Togias A, Sicherer SH, et al. · N Engl J Med · 2024 · Trial result
    PubMed: PMID 38407394 · NCT03881696 (OUtMATCH) · Peanut Hypersensitivity
  2. Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trials.
    Maurer M, Ensina LF, Gimenez-Arnau AM, et al. · Lancet · 2024 · Derived
    PubMed: PMID 38008109 · NCT03580369 · Chronic Urticaria
  3. COVID-19 Immunologic Antiviral Therapy With Omalizumab (CIAO)-a Randomized Controlled Clinical Trial.
    Le M, Khoury L, Lu Y, et al. · Open Forum Infect Dis · 2024 · Derived
    PubMed: PMID 38560604 · NCT04720612 (CIAO) · Coronavirus Infections
  4. New evidence in food allergies treatment.
    Ghelli C, Costanzo G, Canonica GW, et al. · Curr Opin Allergy Clin Immunol · 2024 · Derived
    PubMed: PMID 38814736 · NCT03679676 · Hypersensitivity
  5. Efficacy and safety of a proposed omalizumab biosimilar compared to the reference product in the management of uncontrolled moderate-to-severe allergic asthma: a multicenter, phase III, randomized, double-blind, equivalency clinical trial.
    Ghanei M, Ghalebaghi B, Sami R, et al. · Front Immunol · 2024 · Derived
    PubMed: PMID 39136011 · NCT05813470 · Asthma
  6. Omalizumab improves sinonasal outcomes in patients with chronic rhinosinusitis with nasal polyps regardless of allergic status.
    Gevaert P, Mullol J, Saenz R, et al. · Ann Allergy Asthma Immunol · 2024 · Derived
    PubMed: PMID 37951571 · NCT03478930 · Nasal Polyps
  7. Does Comorbid Food Allergy Affect Response to Omalizumab in Patients with Asthma?
    Fiocchi A, Chinthrajah RS, Ansotegui IJ, et al. · J Asthma Allergy · 2024 · Derived
    PubMed: PMID 39309477 · NCT01922037 · Asthma
  8. Effectiveness of omalizumab across different dosing regimens in patients with moderate-to-severe allergic asthma.
    Chase NM, Littlejohn M, Holweg CTJ, et al. · Respir Med · 2024 · Derived
    PubMed: PMID 38253245 · NCT01922037 · Asthma
  9. Does angioedema in patients with chronic spontaneous urticaria impact response to omalizumab?
    Casale TB, Trzaskoma B, Holden M, et al. · World Allergy Organ J · 2024 · Derived
    PubMed: PMID 39193419 · NCT01292473 · Chronic Urticaria

2023 (4 papers)

  1. Double-Blind, Placebo-Controlled Study of E-B-FAHF-2 in Combination With Omalizumab-Facilitated Multiallergen Oral Immunotherapy.
    Wang J, Wood RA, Raymond S, et al. · J Allergy Clin Immunol Pract · 2023 · Trial result
    PubMed: PMID 37087097 · NCT06103656 (FAHF-2) · Food Hypersensitivity
  2. Similar response to omalizumab in children with allergic asthma from different racial backgrounds.
    Witonsky J, Elhawary JR, Millette LA, et al. · J Allergy Clin Immunol Pract · 2023 · Derived
    PubMed: PMID 37088376 · NCT00079937 · Asthma
  3. A comparison of biologicals in the treatment of adults with severe asthma - real-life experiences.
    Kotisalmi E, Hakulinen A, Mäkelä M, et al. · Asthma Res Pract · 2023 · Derived
    PubMed: PMID 32467765 · NCT04158050 (BiSA) · Asthma
  4. Meaningful changes for efficacy outcomes in patients with chronic rhinosinusitis with nasal polyps.
    Braid J, Islam L, Gugiu C, et al. · World Allergy Organ J · 2023 · Derived
    PubMed: PMID 37214171 · NCT03280537 (POLYP 2) · Nasal Polyps

2022 (16 papers)

  1. Phase 2, randomized multi oral immunotherapy with omalizumab 'real life' study.
    Sindher SB, Kumar D, Cao S, et al. · Allergy · 2022 · Trial result
    PubMed: PMID 35014049 · NCT03181009 · Food Hypersensitivity
  2. Omalizumab for treatment of idiopathic angioedema.
    Goswamy VP, Lee KE, McKernan EM, et al. · Ann Allergy Asthma Immunol · 2022 · Trial result
    PubMed: PMID 35914662 · NCT02966314 · Angioedema
  3. Ligelizumab improves angioedema, disease severity and quality-of-life in patients with chronic spontaneous urticaria.
    Metz M, Bernstein JA, Giménez-Arnau AM, et al. · World Allergy Organ J · 2022 · Derived
    PubMed: PMID 36440464 · NCT02477332 · Chronic Urticaria
  4. Sustained safety and efficacy of ligelizumab in patients with chronic spontaneous urticaria: A one-year extension study.
    Maurer M, Giménez-Arnau A, Bernstein JA, et al. · Allergy · 2022 · Derived
    PubMed: PMID 34773261 · NCT02477332 · Chronic Urticaria
  5. Efficacy predictors of omalizumab in Chinese patients with moderate-to-severe allergic asthma: Findings from a post-hoc analysis of a randomised phase III study.
    Li J, Wang C, Liu C, et al. · World Allergy Organ J · 2022 · Derived
    PubMed: PMID 34611470 · NCT01202903 · Asthma
  6. Protocol for a double-blind, randomized controlled trial on the dose-related efficacy of omalizumab in multi-food oral immunotherapy.
    Langlois A, Lavergne MH, Leroux H, et al. · Allergy Asthma Clin Immunol · 2022 · Derived
    PubMed: PMID 32328115 · NCT04045301 (BOOM)
  7. Omalizumab treatment reduces asthma exacerbations regardless of airway bronchodilator reversibility.
    DeLeon S, Barsanti F, Holweg CTJ, et al. · J Allergy Clin Immunol Pract · 2022 · Derived
    PubMed: PMID 35526776 · NCT01922037 · Asthma
  8. Efficacy and Safety of Dupilumab Versus Omalizumab in Chronic Rhinosinusitis With Nasal Polyps and Asthma: EVEREST Trial Design.
    De Prado Gomez PharmD MSc L, Khan Mbbs Mph AH, Peters Md AT, et al. · Am J Rhinol Allergy · 2022 · Derived
    PubMed: PMID 35837739 · NCT04998604 (EVEREST) · Asthma
  9. Overlap of allergic, eosinophilic and type 2 inflammatory subtypes in moderate-to-severe asthma.
    Chen M, Shepard K, Yang M, et al. · Clin Exp Allergy · 2022 · Derived
    PubMed: PMID 33217063 · NCT01922037 · Asthma
  10. High-resolution epitope mapping by AllerScan reveals relationships between IgE and IgG repertoires during peanut oral immunotherapy.
    Chen G, Shrock EL, Li MZ, et al. · Cell Rep Med · 2022 · Derived
    PubMed: PMID 34755130 · NCT01781637 (PRROTECT) · Food Hypersensitivity
  11. Transcriptome changes during peanut oral immunotherapy and omalizumab treatment.
    Björkander S, Merid SK, Brodin D, et al. · Pediatr Allergy Immunol · 2022 · Derived
    PubMed: PMID 34669990 · NCT02402231 (FASTX) · Peanut Hypersensitivity
  12. A Phase 2 Randomized Controlled Multisite Study Using Omalizumab-facilitated Rapid Desensitization to Test Continued vs Discontinued Dosing in Multifood Allergic Individuals.
    Andorf S, Purington N, Kumar D, et al. · EClinicalMedicine · 2022 · Derived
    PubMed: PMID 31193674 · NCT02626611 (M-TAX) · Food Hypersensitivity
  13. Observational long-term follow-up study of rapid food oral immunotherapy with omalizumab.
    Andorf S, Manohar M, Dominguez T, et al. · Allergy Asthma Clin Immunol · 2022 · Derived
    PubMed: PMID 29296107 · NCT01510626 · Immune System Diseases
  14. Canadian real-world study of access and clinical results using dupilumab for chronic rhinosinusitis with polyps.
    Kilty SJ, Lasso A · J Otolaryngol Head Neck Surg · 2022 · Background
    PubMed: PMID 35468866 · NCT06683261 (RELIBIO)
  15. Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Han JK, Bachert C, Fokkens W, et al. · Lancet Respir Med · 2022 · Background
    PubMed: PMID 33872587 · NCT06683261 (RELIBIO)
  16. Dupilumab efficacy and biomarkers in chronic rhinosinusitis with nasal polyps: Association between dupilumab treatment effect on nasal polyp score and biomarkers of type 2 inflammation in patients with chronic rhinosinusitis with nasal polyps in the phase 3 SINUS-24 and SINUS-52 trials.
    Bachert C, Corren J, Lee SE, et al. · Int Forum Allergy Rhinol · 2022 · Background
    PubMed: PMID 34970860 · NCT06683261 (RELIBIO)

2021 (17 papers)

  1. The efficacy of omalizumab treatment in chronic spontaneous urticaria is associated with basophil phenotypes.
    Johal KJ, Chichester KL, Oliver ET, et al. · J Allergy Clin Immunol · 2021 · Trial result
    PubMed: PMID 33713769 · NCT03111628 · Chronic Urticaria
  2. Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials.
    Gevaert P, Omachi TA, Corren J, et al. · J Allergy Clin Immunol · 2021 · Trial result
    PubMed: PMID 32524991 · NCT05405478 · Nasal Polyps
  3. Traditional Chinese medicine for food allergy and eczema.
    Wang Z, Wang ZZ, Geliebter J, et al. · Ann Allergy Asthma Immunol · 2021 · Derived
    PubMed: PMID 33310179 · NCT02879006 · Food Hypersensitivity
  4. Treatment with the anti-IgE monoclonal antibody omalizumab in women with asthma undergoing fertility treatment: a proof-of-concept study-The PRO-ART study protocol.
    Tidemandsen C, Juul Gade E, Ulrik CS, et al. · BMJ Open · 2021 · Derived
    PubMed: PMID 33184076 · NCT03727971 (PRO_ART) · Asthma
  5. Response to Omalizumab in Black and White Patients with Allergic Asthma.
    Szefler SJ, Jerschow E, Yoo B, et al. · J Allergy Clin Immunol Pract · 2021 · Derived
    PubMed: PMID 34303017 · NCT00314574 · Asthma
  6. Treatment Benefit with Omalizumab in Children by Indicators of Asthma Severity.
    Szefler SJ, Casale TB, Haselkorn T, et al. · J Allergy Clin Immunol Pract · 2021 · Derived
    PubMed: PMID 32298853 · NCT01430403 (PROSE) · Asthma
  7. Omalizumab Re-Treatment and Step-Up in Patients with Chronic Spontaneous Urticaria: OPTIMA Trial.
    Sussman G, Hébert J, Gulliver W, et al. · J Allergy Clin Immunol Pract · 2021 · Derived
    PubMed: PMID 32272284 · NCT02161562 (OPTIMA) · Chronic Urticaria
  8. Omalizumab response in patients with asthma by number and type of allergen.
    Soong W, Yoo B, Pazwash H, et al. · Ann Allergy Asthma Immunol · 2021 · Derived
    PubMed: PMID 33838339 · NCT01922037 · Asthma
  9. Preventing asthma in high risk kids (PARK) with omalizumab: Design, rationale, methods, lessons learned and adaptation.
    Phipatanakul W, Mauger DT, Guilbert TW, et al. · Contemp Clin Trials · 2021 · Derived
    PubMed: PMID 33242697 · NCT02570984 (PARK) · Asthma
  10. Indirect Treatment Comparison of Biologics in Chronic Rhinosinusitis with Nasal Polyps.
    Peters AT, Han JK, Hellings P, et al. · J Allergy Clin Immunol Pract · 2021 · Derived
    PubMed: PMID 33548517 · NCT03280537 (POLYP 2) · Nasal Polyps
  11. Benefit of switching to mepolizumab from omalizumab in severe eosinophilic asthma based on patient characteristics.
    Liu MC, Chipps B, Munoz X, et al. · Respir Res · 2021 · Derived
    PubMed: PMID 33971856 · NCT02654145 · Asthma
  12. Determinants of lung function improvement with omalizumab in adults with allergic asthma.
    Hanania NA, Djukanovic R, Heaney LG, et al. · J Allergy Clin Immunol Pract · 2021 · Derived
    PubMed: PMID 31981731 · NCT01922037 · Asthma
  13. Defining the Efficacy of Omalizumab in Nasal Polyposis: A POLYP 1 and POLYP 2 Subgroup Analysis.
    Damask C, Chen M, Holweg CTJ, et al. · Am J Rhinol Allergy · 2021 · Derived
    PubMed: PMID 34382434 · NCT03280537 (POLYP 2) · Nasal Polyps
  14. Biologics for chronic rhinosinusitis.
    Chong LY, Piromchai P, Sharp S, et al. · Cochrane Database Syst Rev · 2021 · Derived
    PubMed: PMID 33710614 · NCT03280550 (POLYP 1) · Nasal Polyps
  15. No difference in omalizumab efficacy in patients with asthma by number of asthma-related and allergic comorbidities.
    Chen M, Choo E, Yoo B, et al. · Ann Allergy Asthma Immunol · 2021 · Derived
    PubMed: PMID 33465457 · NCT00046748 · Asthma
  16. Possible Protective Effect of Omalizumab on Lung Function Decline in Patients Experiencing Asthma Exacerbations.
    Busse WW, Szefler SJ, Haselkorn T, et al. · J Allergy Clin Immunol Pract · 2021 · Derived
    PubMed: PMID 33223095 · NCT00079937 · Asthma
  17. Adjunct therapy with probiotics for chronic urticaria in children: randomised placebo-controlled trial.
    Bi XD, Lu BZ, Pan XX, et al. · Allergy Asthma Clin Immunol · 2021 · Derived
    PubMed: PMID 33865434 · NCT03328897 · Chronic Urticaria

2020 (12 papers)

  1. Omalizumab in patients with severe asthma and persistent sputum eosinophilia.
    Mukherjee M, Kjarsgaard M, Radford K, et al. · Allergy Asthma Clin Immunol · 2020 · Derived
    PubMed: PMID 30988677 · NCT02049294 · Asthma
  2. Safety and Tolerability of Omalizumab: A Randomized Clinical Trial of Humanized Anti-IgE Monoclonal Antibody in Systemic Lupus Erythematosus.
    Hasni S, Gupta S, Davis M, et al. · Arthritis Rheumatol · 2020 · Derived
    PubMed: PMID 30597768 · NCT01716312 · Lupus Erythematosus, Systemic
  3. Omalizumab effectiveness in asthma-COPD overlap: Post hoc analysis of PROSPERO.
    Hanania NA, Chipps BE, Griffin NM, et al. · J Allergy Clin Immunol · 2020 · Derived
    PubMed: PMID 30576755 · NCT01922037 · Asthma
  4. Impact of omalizumab on patient-reported outcomes in chronic idiopathic urticaria: Results from a randomized study (XTEND-CIU).
    Casale TB, Murphy TR, Holden M, et al. · J Allergy Clin Immunol Pract · 2020 · Derived
    PubMed: PMID 31034999 · NCT02392624 · Urticaria
  5. Effect of omalizumab on lung function and eosinophil levels in adolescents with moderate-to-severe allergic asthma.
    Busse WW, Humbert M, Haselkorn T, et al. · Ann Allergy Asthma Immunol · 2020 · Derived
    PubMed: PMID 31760132 · NCT00314574 · Asthma
  6. Individually dosed omalizumab facilitates peanut oral immunotherapy in peanut allergic adolescents.
    Brandström J, Vetander M, Sundqvist AC, et al. · Clin Exp Allergy · 2020 · Derived
    PubMed: PMID 31329313 · NCT02402231 (FASTX) · Peanut Hypersensitivity
  7. The Consortium for Food Allergy Research (CoFAR): The first generation.
    Sampson HA, Berin MC, Plaut M, et al. · J Allergy Clin Immunol · 2020 · Background
    PubMed: PMID 30586557 · NCT03881696 (OUtMATCH) · Peanut Hypersensitivity
  8. Pharmacological advances in pemphigoid.
    Maglie R, Hertl M · Curr Opin Pharmacol · 2020 · Background
    PubMed: PMID 30769277 · NCT04128176 · Pemphigoid, Bullous
  9. Diagnosis and management of NSAID-Exacerbated Respiratory Disease (N-ERD)-a EAACI position paper.
    Kowalski ML, Agache I, Bavbek S, et al. · Allergy · 2020 · Background
    PubMed: PMID 30216468 · NCT06683261 (RELIBIO)
  10. European Position Paper on Rhinosinusitis and Nasal Polyps 2020.
    Fokkens WJ, Lund VJ, Hopkins C, et al. · Rhinology · 2020 · Background
    PubMed: PMID 32077450 · NCT04583501 (CRSwNP) · Nasal Polyps
  11. Impact of Omalizumab on Food Allergy in Patients Treated for Asthma: A Real-Life Study.
    Fiocchi A, Artesani MC, Riccardi C, et al. · J Allergy Clin Immunol Pract · 2020 · Background
    PubMed: PMID 30797778 · NCT06316414 (OSAFA) · Hypersensitivity
  12. Twelve-year follow-up of omalizumab therapy for anaphylaxis in 2 patients with systemic mastocytosis.
    Constantine GM, Bressler PB, Petroni D, et al. · J Allergy Clin Immunol Pract · 2020 · Background
    PubMed: PMID 30149096 · NCT00890162 · Hypersensitivity

2019 (10 papers)

  1. The basophil proteome in chronic spontaneous urticaria distinguishes responders to omalizumab from non-responders.
    Stitt JM, Dzieciatkowska M, Edwards MG, et al. · Clin Exp Allergy · 2019 · Trial result
    PubMed: PMID 29671921 · NCT01701583 · Chronic Urticaria
  2. Omalizumab is effective in cold urticaria-results of a randomized placebo-controlled trial.
    Metz M, Schütz A, Weller K, et al. · J Allergy Clin Immunol · 2019 · Derived
    PubMed: PMID 28389393 · NCT01580592 (CUTEX) · Cold Urticaria
  3. Omalizumab is effective in symptomatic dermographism-results of a randomized placebo-controlled trial.
    Maurer M, Schütz A, Weller K, et al. · J Allergy Clin Immunol · 2019 · Derived
    PubMed: PMID 28389391 · NCT02169115 (UFO) · Familial dermographism
  4. Ligelizumab for Chronic Spontaneous Urticaria.
    Maurer M, Giménez-Arnau AM, Sussman G, et al. · N Engl J Med · 2019 · Derived
    PubMed: PMID 31577874 · NCT02477332 · Chronic Urticaria
  5. Childhood Asthma Inception and Progression: Role of Microbial Exposures, Susceptibility to Viruses and Early Allergic Sensitization.
    Martinez FD · Immunol Allergy Clin North Am · 2019 · Derived
    PubMed: PMID 30954166 · NCT02570984 (PARK) · Asthma
  6. Baseline asthma burden, comorbidities, and biomarkers in omalizumab-treated patients in PROSPERO.
    Luskin AT, Chipps BE, Casale TB, et al. · Ann Allergy Asthma Immunol · 2019 · Derived
    PubMed: PMID 29421314 · NCT01922037 · Asthma
  7. Omalizumab can inhibit respiratory reaction during aspirin desensitization.
    Lang DM, Aronica MA, Maierson ES, et al. · Ann Allergy Asthma Immunol · 2019 · Derived
    PubMed: PMID 29777744 · NCT00555971
  8. Predicting Chronic Spontaneous Urticaria Symptom Return After Omalizumab Treatment Discontinuation: Exploratory Analysis.
    Ferrer M, Giménez-Arnau A, Saldana D, et al. · J Allergy Clin Immunol Pract · 2019 · Derived
    PubMed: PMID 29655772 · NCT01264939 · Chronic Urticaria
  9. Oral immunotherapy with omalizumab reverses the Th2 cell-like programme of regulatory T cells and restores their function.
    Abdel-Gadir A, Schneider L, Casini A, et al. · Clin Exp Allergy · 2019 · Derived
    PubMed: PMID 29700872 · NCT01290913 · Peanut Hypersensitivity
  10. The Global Allergy and Asthma European Network (GALEN rhinosinusitis cohort: a large European cross-sectional study of chronic rhinosinusitis patients with and without nasal polyps.
    Khan A, Vandeplas G, Huynh TMT, et al. · Rhinology · 2019 · Background
    PubMed: PMID 29911211 · NCT06683261 (RELIBIO)

2018 (3 papers)

  1. Effect of Omalizumab on Blood Basophil Counts in Patients with Chronic Idiopathic/Spontaneous Urticaria.
    Saini SS, Omachi TA, Trzaskoma B, et al. · J Invest Dermatol · 2018 · Derived
    PubMed: PMID 27939380 · NCT01264939 · Chronic Urticaria
  2. Omalizumab reduces bronchial mucosal IgE and improves lung function in non-atopic asthma.
    Pillai P, Chan YC, Wu SY, et al. · Eur Respir J · 2018 · Derived
    PubMed: PMID 27824606 · NCT01113437 · Asthma
  3. Clinical Characteristics of Patients with Chronic Rhinosinusitis with Nasal Polyps, Asthma, and Aspirin-Exacerbated Respiratory Disease.
    Stevens WW, Peters AT, Hirsch AG, et al. · J Allergy Clin Immunol Pract · 2018 · Background
    PubMed: PMID 28286156 · NCT06683261 (RELIBIO)

2017 (9 papers)

  1. Angioedema in the omalizumab chronic idiopathic/spontaneous urticaria pivotal studies.
    Zazzali JL, Kaplan A, Maurer M, et al. · Ann Allergy Asthma Immunol · 2017 · Derived
    PubMed: PMID 27424128 · NCT01287117 · Chronic Urticaria
  2. Effect of omalizumab on angioedema in H1 -antihistamine-resistant chronic spontaneous urticaria patients: results from X-ACT, a randomized controlled trial.
    Staubach P, Metz M, Chapman-Rothe N, et al. · Allergy · 2017 · Derived
    PubMed: PMID 27010957 · NCT01723072 (X-ACT) · Chronic Urticaria
  3. Long-term safety, efficacy, pharmacokinetics and pharmacodynamics of omalizumab in children with severe uncontrolled asthma.
    Odajima H, Ebisawa M, Nagakura T, et al. · Allergol Int · 2017 · Derived
    PubMed: PMID 27507228 · NCT01328886
  4. Clinical features of adolescents with chronic idiopathic or spontaneous urticaria: Review of omalizumab clinical trials.
    Goldstein S, Gabriel S, Kianifard F, et al. · Ann Allergy Asthma Immunol · 2017 · Derived
    PubMed: PMID 28390587 · NCT01292473 · Chronic Urticaria
  5. Effects of Omalizumab on Rhinovirus Infections, Illnesses, and Exacerbations of Asthma.
    Esquivel A, Busse WW, Calatroni A, et al. · Am J Respir Crit Care Med · 2017 · Derived
    PubMed: PMID 28608756 · NCT01430403 (PROSE) · Asthma
  6. Baseline asthma burden, comorbidities, and biomarkers in omalizumab-treated patients in PROSPERO.
    Chipps BE, Zeiger RS, Luskin AT, et al. · Ann Allergy Asthma Immunol · 2017 · Derived
    PubMed: PMID 29054589 · NCT01922037 · Asthma
  7. Individually dosed omalizumab: an effective treatment for severe peanut allergy.
    Brandström J, Vetander M, Lilja G, et al. · Clin Exp Allergy · 2017 · Derived
    PubMed: PMID 27883239 · NCT02402231 (FASTX) · Peanut Hypersensitivity
  8. Inflammatory endotypes of chronic rhinosinusitis based on cluster analysis of biomarkers.
    Tomassen P, Vandeplas G, Van Zele T, et al. · J Allergy Clin Immunol · 2017 · Background
    PubMed: PMID 26949058 · NCT06683261 (RELIBIO)
  9. Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria.
    Kaplan AP, Giménez-Arnau AM, Saini SS, et al. · Allergy · 2017 · Background
    PubMed: PMID 27861988 · NCT03111628 · Chronic Urticaria

2016 (9 papers)

  1. A randomized, double-blind, placebo-controlled study of omalizumab combined with oral immunotherapy for the treatment of cow's milk allergy.
    Wood RA, Kim JS, Lindblad R, et al. · J Allergy Clin Immunol · 2016 · Trial result
    PubMed: PMID 26581915 · NCT01157117 · Food Hypersensitivity
  2. Preseasonal treatment with either omalizumab or an inhaled corticosteroid boost to prevent fall asthma exacerbations.
    Teach SJ, Gill MA, Togias A, et al. · J Allergy Clin Immunol · 2016 · Trial result
    PubMed: PMID 26518090 · NCT01430403 (PROSE) · Asthma
  3. Omalizumab in Japanese children with severe allergic asthma uncontrolled with standard therapy.
    Odajima H, Ebisawa M, Nagakura T, et al. · Allergol Int · 2016 · Trial result
    PubMed: PMID 26433533 · NCT01155700
  4. Pharmacokinetics, Pharmacodynamics, and Safety of MEDI4212, an Anti-IgE Monoclonal Antibody, in Subjects with Atopy: A Phase I Study.
    Sheldon E, Schwickart M, Li J, et al. · Adv Ther · 2016 · Derived
    PubMed: PMID 26843086 · NCT01544348 · Dermatitis, Atopic
  5. Epinephrine use in positive oral food challenges performed as a screening test for food allergy therapy trials.
    Noone S, Ross J, Sampson HA, et al. · J Allergy Clin Immunol Pract · 2016 · Derived
    PubMed: PMID 25609353 · NCT01157117 · Food Hypersensitivity
  6. A pilot study of omalizumab in eosinophilic esophagitis.
    Loizou D, Enav B, Komlodi-Pasztor E, et al. · PLoS One · 2016 · Derived
    PubMed: PMID 25789989 · NCT01040598 · Eosinophilic Esophagitis
  7. Improvement of sleep in patients with chronic idiopathic/spontaneous urticaria treated with omalizumab: results of three randomized, double-blind, placebo-controlled studies.
    Gimenéz-Arnau AM, Spector S, Antonova E, et al. · Clin Transl Allergy · 2016 · Derived
    PubMed: PMID 27540466 · NCT01264939 · Chronic Urticaria
  8. Similar Efficacy with Omalizumab in Chronic Idiopathic/Spontaneous Urticaria Despite Different Background Therapy.
    Casale TB, Bernstein JA, Maurer M, et al. · J Allergy Clin Immunol Pract · 2016 · Derived
    PubMed: PMID 26054553 · NCT01287117 · Chronic Urticaria
  9. International Consensus Statement on Allergy and Rhinology: Rhinosinusitis.
    Orlandi RR, Kingdom TT, Hwang PH, et al. · Int Forum Allergy Rhinol · 2016 · Background
    PubMed: PMID 26889651 · NCT04583501 (CRSwNP) · Nasal Polyps

2015 (4 papers)

  1. Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study.
    Saini SS, Bindslev-Jensen C, Maurer M, et al. · J Invest Dermatol · 2015 · Derived
    PubMed: PMID 25046337 · NCT01287117 · Chronic Urticaria
  2. Omalizumab in patients with allergic (IgE-mediated) asthma and IgE/bodyweight combinations above those in the initially approved dosing table.
    Kornmann O, Watz H, Fuhr R, et al. · Pulm Pharmacol Ther · 2015 · Derived
    PubMed: PMID 24657236 · NCT00546143 · Asthma
  3. Omalizumab therapy for asthma patients with poor adherence to inhaled corticosteroid therapy.
    Hendeles L, Khan YR, Shuster JJ, et al. · Ann Allergy Asthma Immunol · 2015 · Derived
    PubMed: PMID 25528738 · NCT00133042 · Asthma
  4. Steroid sparing effect of omalizumab in seropositive allergic bronchopulmonary aspergillosis.
    Beam KT, Coop CA · Allergy Rhinol (Providence) · 2015 · Derived
    PubMed: PMID 26302738 · NCT00787917 · Aspergillosis, Allergic Bronchopulmonary

2014 (5 papers)

  1. Immunogenicity and safety of omalizumab in pre-filled syringes in patients with allergic (IgE-mediated) asthma.
    Somerville L, Bardelas J, Viegas A, et al. · Curr Med Res Opin · 2014 · Derived
    PubMed: PMID 24028677 · NCT00500539 · Asthma
  2. A proof-of-concept, randomized, controlled trial of omalizumab in patients with severe, difficult-to-control, nonatopic asthma.
    Garcia G, Magnan A, Chiron R, et al. · Chest · 2014 · Derived
    PubMed: PMID 23579324 · NCT01007149 (NATAIR) · Asthma
  3. Eosinophilic esophagitis in adults is associated with IgG4 and not mediated by IgE.
    Clayton F, Fang JC, Gleich GJ, et al. · Gastroenterology · 2014 · Derived
    PubMed: PMID 24907494 · NCT00123630 · Eosinophilic Esophagitis
  4. A retrospective study of patients with a delayed diagnosis of allergic bronchopulmonary aspergillosis/allergic bronchopulmonary mycosis.
    Mou Y, Ye L, Ye M, et al. · Allergy Asthma Proc · 2014 · Background
    PubMed: PMID 24717781 · NCT05129033 · Aspergillosis, Allergic Bronchopulmonary
  5. Allergic bronchopulmonary aspergillosis: review of literature and proposal of new diagnostic and classification criteria.
    Agarwal R, Chakrabarti A, Shah A, et al. · Clin Exp Allergy · 2014 · Background
    PubMed: PMID 23889240 · NCT05129033 · Aspergillosis, Allergic Bronchopulmonary

2013 (5 papers)

  1. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria.
    Maurer M, Rosén K, Hsieh HJ, et al. · N Engl J Med · 2013 · Derived
    PubMed: PMID 23432142 · NCT01292473 · Chronic Urticaria
  2. Omalizumab increases the intrinsic sensitivity of human basophils to IgE-mediated stimulation.
    Macglashan DW, Saini SS · J Allergy Clin Immunol · 2013 · Derived
    PubMed: PMID 23791510 · NCT01003301
  3. Immunologic effects of omalizumab in children with severe refractory atopic dermatitis: a randomized, placebo-controlled clinical trial.
    Iyengar SR, Hoyte EG, Loza A, et al. · Int Arch Allergy Immunol · 2013 · Derived
    PubMed: PMID 23816920 · NCT01678092 (OXAD) · Dermatitis, Atopic
  4. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study.
    Hanania NA, Wenzel S, Rosén K, et al. · Am J Respir Crit Care Med · 2013 · Derived
    PubMed: PMID 23471469 · NCT00314574 · Asthma
  5. Influence of asthma on quality of life and clinical characteristics of patients with nasal polyposis.
    Dudvarski Z, Djukic V, Janosevic L, et al. · Eur Arch Otorhinolaryngol · 2013 · Background
    PubMed: PMID 23135235 · NCT06683261 (RELIBIO)

2012 (4 papers)

  1. Oral corticosteroid sparing with omalizumab in severe allergic (IgE-mediated) asthma patients.
    Siergiejko Z, Świebocka E, Smith N, et al. · Curr Med Res Opin · 2012 · Derived
    PubMed: PMID 21933100 · NCT00264849 · Asthma
  2. Changes in antigen-specific T-cell number and function during oral desensitization in cow's milk allergy enabled with omalizumab.
    Bedoret D, Singh AK, Shaw V, et al. · Mucosal Immunol · 2012 · Derived
    PubMed: PMID 22318492 · NCT00968110 · Milk Hypersensitivity
  3. Evaluating the minimally important difference of the urticaria activity score and other measures of disease activity in patients with chronic idiopathic urticaria.
    Mathias SD, Crosby RD, Zazzali JL, et al. · Ann Allergy Asthma Immunol · 2012 · Background
    PubMed: PMID 22192960 · NCT01713725 · Chronic Urticaria
  4. EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists.
    Fokkens WJ, Lund VJ, Mullol J, et al. · Rhinology · 2012 · Background
    PubMed: PMID 22469599 · NCT06683261 (RELIBIO)

2011 (12 papers)

  1. Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children.
    Busse WW, Morgan WJ, Gergen PJ, et al. · N Engl J Med · 2011 · Trial result
    PubMed: PMID 21410369 · NCT00377572 (ICATA) · Asthma
  2. A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria.
    Saini S, Rosen KE, Hsieh HJ, et al. · J Allergy Clin Immunol · 2011 · Derived
    PubMed: PMID 21762974 · NCT00130234 · Urticaria
  3. Cat allergen-induced blood basophil reactivity in vitro predicts acute human nasal allergen challenge responses in vivo.
    Paterniti M, Kelly DC, Eckman JA, et al. · Clin Exp Allergy · 2011 · Derived
    PubMed: PMID 21668817 · NCT00604786 · Rhinitis, Allergic
  4. Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial.
    Hanania NA, Alpan O, Hamilos DL, et al. · Ann Intern Med · 2011 · Derived
    PubMed: PMID 21536936 · NCT00314574 · Asthma
  5. Effect of anti-IgE therapy on food allergen specific T cell responses in eosinophil associated gastrointestinal disorders.
    Foster B, Foroughi S, Yin Y, et al. · Clin Mol Allergy · 2011 · Derived
    PubMed: PMID 21527026 · NCT00084097 · Hypersensitivity
  6. Omalizumab-induced decrease of FcξRI expression in patients with severe allergic asthma.
    Chanez P, Contin-Bordes C, Garcia G, et al. · Respir Med · 2011 · Derived
    PubMed: PMID 20801010 · NCT00454051 · Asthma
  7. Mucosal tissue polyclonal IgE is functional in response to allergen and SEB.
    Zhang N, Holtappels G, Gevaert P, et al. · Allergy · 2011 · Background
    PubMed: PMID 20659077 · NCT06683261 (RELIBIO)
  8. Pathogenesis of bullous pemphigoid.
    Ujiie H, Nishie W, Shimizu H, et al. · Dermatol Clin · 2011 · Background
    PubMed: PMID 21605809 · NCT04128176 · Pemphigoid, Bullous
  9. Chronic rhinosinusitis in Europe--an underestimated disease. A GA²LEN study.
    Hastan D, Fokkens WJ, Bachert C, et al. · Allergy · 2011 · Background
    PubMed: PMID 21605125 · NCT06683261 (RELIBIO)
  10. Basophil CD203c levels are increased at baseline and can be used to monitor omalizumab treatment in subjects with nut allergy.
    Gernez Y, Tirouvanziam R, Yu G, et al. · Int Arch Allergy Immunol · 2011 · Background
    PubMed: PMID 20975283 · NCT01716312 · Lupus Erythematosus, Systemic
  11. Omalizumab is effective in nonautoimmune urticaria.
    Ferrer M, Gamboa P, Sanz ML, et al. · J Allergy Clin Immunol · 2011 · Background
    PubMed: PMID 21315432 · NCT01713725 · Chronic Urticaria
  12. A review of anti-IgE monoclonal antibody (omalizumab) as add on therapy for severe allergic (IgE-mediated) asthma.
    D'Amato G, Salzillo A, Piccolo A, et al. · Ther Clin Risk Manag · 2011 · Background
    PubMed: PMID 18472983 · NCT01716312 · Lupus Erythematosus, Systemic

2010 (5 papers)

  1. Eosinophilic gastrointestinal disease and peanut allergy are alternatively associated with IL-5+ and IL-5(-) T(H)2 responses.
    Prussin C, Lee J, Foster B, et al. · J Allergy Clin Immunol · 2010 · Derived
    PubMed: PMID 20004787 · NCT00084097 · Hypersensitivity
  2. A randomized, double-blind, placebo-controlled trial of anti-IgE for chronic rhinosinusitis.
    Pinto JM, Mehta N, DiTineo M, et al. · Rhinology · 2010 · Derived
    PubMed: PMID 21038023 · NCT00117611 · Sinusitis
  3. Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma.
    Lanier B, Bridges T, Kulus M, et al. · J Allergy Clin Immunol · 2010 · Derived
    PubMed: PMID 19910033 · NCT00079937 · Asthma
  4. Basophils and the T helper 2 environment can promote the development of lupus nephritis.
    Charles N, Hardwick D, Daugas E, et al. · Nat Med · 2010 · Background
    PubMed: PMID 20512127 · NCT01716312 · Lupus Erythematosus, Systemic
  5. Aspergillus hypersensitivity and allergic bronchopulmonary aspergillosis in patients with acute severe asthma in a respiratory intensive care unit in North India.
    Agarwal R, Nath A, Aggarwal AN, et al. · Mycoses · 2010 · Background
    PubMed: PMID 19207831 · NCT05129033 · Aspergillosis, Allergic Bronchopulmonary

2009 (4 papers)

  1. Adaptation and validation of the Spanish version of the Chronic Urticaria Quality of Life Questionnaire (CU-Q2oL).
    Valero A, Herdman M, Bartra J, et al. · J Investig Allergol Clin Immunol · 2009 · Background
    PubMed: PMID 19123433 · NCT01713725 · Chronic Urticaria
  2. Epidemiology, healthcare, resources, use and clinical features of different types of urticaria. Alergológica 2005.
    Ferrer M · J Investig Allergol Clin Immunol · 2009 · Background
    PubMed: PMID 19530414 · NCT01713725 · Chronic Urticaria
  3. Allergic bronchopulmonary aspergillosis.
    Agarwal R · Chest · 2009 · Background
    PubMed: PMID 19265090 · NCT05129033 · Aspergillosis, Allergic Bronchopulmonary
  4. Aspergillus hypersensitivity and allergic bronchopulmonary aspergillosis in patients with bronchial asthma: systematic review and meta-analysis.
    Agarwal R, Aggarwal AN, Gupta D, et al. · Int J Tuberc Lung Dis · 2009 · Background
    PubMed: PMID 19723372 · NCT05129033 · Aspergillosis, Allergic Bronchopulmonary

2007 (5 papers)

  1. Combination treatment with omalizumab and rush immunotherapy for ragweed-induced allergic rhinitis: Inhibition of IgE-facilitated allergen binding.
    Klunker S, Saggar LR, Seyfert-Margolis V, et al. · J Allergy Clin Immunol · 2007 · Trial result
    PubMed: PMID 17631952 · NCT00078195 · Hypersensitivity
  2. Objective monitoring of nasal patency and nasal physiology in rhinitis.
    Nathan RA, Eccles R, Howarth PH, et al. · J Allergy Clin Immunol · 2007 · Background
    PubMed: PMID 15746882 · NCT00604786 · Rhinitis, Allergic
  3. Rhinosinusitis: Developing guidance for clinical trials.
    Meltzer EO, Hamilos DL, Hadley JA, et al. · Otolaryngol Head Neck Surg · 2007 · Background
    PubMed: PMID 17081855 · NCT04583501 (CRSwNP) · Nasal Polyps
  4. Omalizumab for the treatment of unprovoked anaphylaxis in patients with systemic mastocytosis.
    Carter MC, Robyn JA, Bressler PB, et al. · J Allergy Clin Immunol · 2007 · Background
    PubMed: PMID 17481708 · NCT00890162 · Hypersensitivity
  5. Clinical significance of hyperattenuating mucoid impaction in allergic bronchopulmonary aspergillosis: an analysis of 155 patients.
    Agarwal R, Gupta D, Aggarwal AN, et al. · Chest · 2007 · Background
    PubMed: PMID 17646221 · NCT05129033 · Aspergillosis, Allergic Bronchopulmonary

2006 (10 papers)

  1. Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis.
    Casale TB, Busse WW, Kline JN, et al. · J Allergy Clin Immunol · 2006 · Trial result
    PubMed: PMID 16387596 · NCT00078195 · Hypersensitivity
  2. Anaphylaxis: a review of 601 cases.
    Webb LM, Lieberman P · Ann Allergy Asthma Immunol · 2006 · Background
    PubMed: PMID 16892779 · NCT00890162 · Hypersensitivity
  3. Omalizumab for asthma.
    Strunk RC, Bloomberg GR · N Engl J Med · 2006 · Background
    PubMed: PMID 16790701 · NCT00604786 · Rhinitis, Allergic
  4. Second symposium on the definition and management of anaphylaxis: summary report--Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium.
    Sampson HA, Muñoz-Furlong A, Campbell RL, et al. · J Allergy Clin Immunol · 2006 · Background
    PubMed: PMID 16461139 · NCT01003301
  5. Nasal lavage fluid concentrations of eotaxin-1 (CCL11) in naturally occurring allergic rhinitis: relationship to disease activity, nasal luminal eosinophil influx, and plasma protein exudation.
    Salib RJ, Lau LC, Howarth PH, et al. · Clin Exp Allergy · 2006 · Background
    PubMed: PMID 16120080 · NCT00604786 · Rhinitis, Allergic
  6. Systemic reactions from skin testing: literature review.
    Liccardi G, D'Amato G, Canonica GW, et al. · J Investig Allergol Clin Immunol · 2006 · Background
    PubMed: PMID 16689179 · NCT01003301
  7. Treatment of recalcitrant atopic dermatitis with omalizumab.
    Lane JE, Cheyney JM, Lane TN, et al. · J Am Acad Dermatol · 2006 · Background
    PubMed: PMID 16384758 · NCT00822783 · Dermatitis, Atopic
  8. Failure of omalizumab for treatment of severe adult atopic dermatitis.
    Krathen RA, Hsu S · J Am Acad Dermatol · 2006 · Background
    PubMed: PMID 16021135 · NCT00822783 · Dermatitis, Atopic
  9. The BODE index after lung volume reduction surgery correlates with survival.
    Imfeld S, Bloch KE, Weder W, et al. · Chest · 2006 · Background
    PubMed: PMID 16608932 · NCT00851370 · Pulmonary Disease, Chronic Obstructive
  10. Safety and tolerability of omalizumab (Xolair), a recombinant humanized monoclonal anti-IgE antibody.
    Deniz YM, Gupta N · Clin Rev Allergy Immunol · 2006 · Background
    PubMed: PMID 16222082 · NCT00604786 · Rhinitis, Allergic

2005 (15 papers)

  1. Anaphylaxis in adults referred to a clinical immunology/allergy centre in Singapore.
    Thong BY, Cheng YK, Leong KP, et al. · Singapore Med J · 2005 · Background
    PubMed: PMID 16172772 · NCT00890162 · Hypersensitivity
  2. Advances in pediatric and adult asthma.
    Szefler SJ, Apter A · J Allergy Clin Immunol · 2005 · Background
    PubMed: PMID 15753890 · NCT00377572 (ICATA) · Asthma
  3. Anti-IgE (omalizumab) inhibits late-phase reactions and inflammatory cells after repeat skin allergen challenge.
    Ong YE, Menzies-Gow A, Barkans J, et al. · J Allergy Clin Immunol · 2005 · Background
    PubMed: PMID 16159624 · NCT01003301
  4. Dose dependence and time course of the immunologic response to administration of standardized cat allergen extract.
    Nanda A, O'connor M, Anand M, et al. · J Allergy Clin Immunol · 2005 · Background
    PubMed: PMID 15577832 · NCT01003301
  5. Prevalence of asthma and asthma-like symptoms in inner-city schoolchildren.
    Mvula M, Larzelere M, Kraus M, et al. · J Asthma · 2005 · Background
    PubMed: PMID 15801322 · NCT00377390 · Asthma
  6. Rhinosinusitis: establishing definitions for clinical research and patient care.
    Meltzer EO, Hamilos DL, Hadley JA, et al. · J Allergy Clin Immunol · 2005 · Background
    PubMed: PMID 15577865 · NCT04583501 (CRSwNP) · Nasal Polyps
  7. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE.
    Humbert M, Beasley R, Ayres J, et al. · Allergy · 2005 · Background
    PubMed: PMID 15679715 · NCT01003301
  8. Anti-immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti-inflammatory activity and clinical efficacy.
    Holgate ST, Djukanović R, Casale T, et al. · Clin Exp Allergy · 2005 · Background
    PubMed: PMID 15836747 · NCT00472030 · Pemphigoid, Bullous
  9. Epidemiology of urticaria in Spain.
    Gaig P, Olona M, Muñoz Lejarazu D, et al. · J Investig Allergol Clin Immunol · 2005 · Background
    PubMed: PMID 15552715 · NCT01713725 · Chronic Urticaria
  10. Mapping the binding sites of anti-BP180 immunoglobulin E autoantibodies in bullous pemphigoid.
    Fairley JA, Fu CL, Giudice GJ, et al. · J Invest Dermatol · 2005 · Background
    PubMed: PMID 16117787 · NCT00472030 · Pemphigoid, Bullous
  11. Childhood asthma: treatment update.
    Courtney AU, McCarter DF, Pollart SM, et al. · Am Fam Physician · 2005 · Background
    PubMed: PMID 15926412 · NCT00377390 · Asthma
  12. The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma.
    Bousquet J, Cabrera P, Berkman N, et al. · Allergy · 2005 · Background
    PubMed: PMID 15679714 · NCT01003301
  13. The risk/benefit of inhaled corticosteroids in chronic obstructive pulmonary disease.
    Bonay M, Bancal C, Crestani B, et al. · Expert Opin Drug Saf · 2005 · Background
    PubMed: PMID 15794718 · NCT00851370 · Pulmonary Disease, Chronic Obstructive
  14. Standardization of food challenges in patients with immediate reactions to foods--position paper from the European Academy of Allergology and Clinical Immunology.
    Bindslev-Jensen C, Ballmer-Weber BK, Bengtsson U, et al. · Allergy · 2005 · Background
    PubMed: PMID 15180754 · NCT03964051 · Food Hypersensitivity
  15. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma.
    Ayres JG, Higgins B, Chilvers ER, et al. · Allergy · 2005 · Background
    PubMed: PMID 15180756 · NCT00377572 (ICATA) · Asthma

2004 (9 papers)

  1. Tolerability of retreatment with omalizumab, a recombinant humanized monoclonal anti-IgE antibody, during a second ragweed pollen season in patients with seasonal allergic rhinitis.
    Nayak A, Casale T, Miller SD, et al. · Allergy Asthma Proc · 2004 · Trial result
    PubMed: PMID 14619332 · NCT00078195 · Hypersensitivity
  2. Omalizumab treatment downregulates dendritic cell FcepsilonRI expression.
    Prussin C, Griffith DT, Boesel KM, et al. · J Allergy Clin Immunol · 2004 · Background
    PubMed: PMID 14657874 · NCT01003301
  3. RANTES, eotaxin and eotaxin-2 expression and production in patients with aspirin triad.
    Pods R, Ross D, van Hülst S, et al. · Allergy · 2004 · Background
    PubMed: PMID 14616128 · NCT00604786 · Rhinitis, Allergic
  4. Omalizumab rapidly decreases nasal allergic response and FcepsilonRI on basophils.
    Lin H, Boesel KM, Griffith DT, et al. · J Allergy Clin Immunol · 2004 · Background
    PubMed: PMID 14767445 · NCT00604786 · Rhinitis, Allergic
  5. Omalizumab inhibits allergen challenge-induced nasal response.
    Hanf G, Noga O, O'Connor A, et al. · Eur Respir J · 2004 · Background
    PubMed: PMID 15065831 · NCT00604786 · Rhinitis, Allergic
  6. Effects of omalizumab, a humanized monoclonal anti-IgE antibody, on nasal reactivity to allergen and local IgE synthesis.
    Corren J, Diaz-Sanchez D, Saxon A, et al. · Ann Allergy Asthma Immunol · 2004 · Background
    PubMed: PMID 15478383 · NCT01003301
  7. Inhaled combination therapy with long-acting beta 2-agonists and corticosteroids in stable COPD.
    Cazzola M, Dahl R · Chest · 2004 · Background
    PubMed: PMID 15249466 · NCT00851370 · Pulmonary Disease, Chronic Obstructive
  8. Omalizumab-induced reductions in mast cell Fce psilon RI expression and function.
    Beck LA, Marcotte GV, MacGlashan D, et al. · J Allergy Clin Immunol · 2004 · Background
    PubMed: PMID 15356552 · NCT00130234 · Urticaria
  9. Quality of life and patients' satisfaction in chronic urticaria and respiratory allergy.
    Baiardini I, Giardini A, Pasquali M, et al. · Allergy · 2004 · Background
    PubMed: PMID 12823121 · NCT00130234 · Urticaria

2003 (7 papers)

  1. Aspirin desensitization in patients with AERD.
    Stevenson DD · Clin Rev Allergy Immunol · 2003 · Background
    PubMed: PMID 12668896 · NCT00286416 · Asthma
  2. Omalizumab: anti-IgE monoclonal antibody E25, E25, humanised anti-IgE MAb, IGE 025, monoclonal antibody E25, Olizumab, Xolair, rhuMAb-E25.
    BioDrugs · 2003 · Background
    PubMed: PMID 12408744 · NCT01003301
  3. Effect of anti-IgE therapy in patients with peanut allergy.
    Leung DY, Sampson HA, Yunginger JW, et al. · N Engl J Med · 2003 · Background
    PubMed: PMID 12637608 · NCT00949078 · Hypersensitivity
  4. Overcoming childhood asthma disparities of the inner-city poor.
    Federico MJ, Liu AH · Pediatr Clin North Am · 2003 · Background
    PubMed: PMID 12877240 · NCT00377390 · Asthma
  5. Identification of a potential effector function for IgE autoantibodies in the organ-specific autoimmune disease bullous pemphigoid.
    Dimson OG, Giudice GJ, Fu CL, et al. · J Invest Dermatol · 2003 · Background
    PubMed: PMID 12713582 · NCT00472030 · Pemphigoid, Bullous
  6. Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis.
    Chervinsky P, Casale T, Townley R, et al. · Ann Allergy Asthma Immunol · 2003 · Background
    PubMed: PMID 12952110 · NCT01003301
  7. Long-term treatment with aspirin desensitization in asthmatic patients with aspirin-exacerbated respiratory disease.
    Berges-Gimeno MP, Simon RA, Stevenson DD, et al. · J Allergy Clin Immunol · 2003 · Background
    PubMed: PMID 12532116 · NCT00286416 · Asthma

2002 (7 papers)

  1. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics.
    Solèr M, Matz J, Townley R, et al. · Eur Respir J · 2002 · Background
    PubMed: PMID 11529281 · NCT00117611 · Sinusitis
  2. Classification of anti-FcepsilonRI and anti-IgE autoantibodies in chronic idiopathic urticaria and correlation with disease severity.
    Sabroe RA, Fiebiger E, Francis DM, et al. · J Allergy Clin Immunol · 2002 · Background
    PubMed: PMID 12209101 · NCT00130234 · Urticaria
  3. Psychometric and clinimetric validity of the 20-Item Sino-Nasal Outcome Test (SNOT-20).
    Piccirillo JF, Merritt MG, Richards ML, et al. · Otolaryngol Head Neck Surg · 2002 · Background
    PubMed: PMID 11821764 · NCT00117611 · Sinusitis
  4. Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis.
    Kuehr J, Brauburger J, Zielen S, et al. · J Allergy Clin Immunol · 2002 · Background
    PubMed: PMID 11842297 · NCT01003301
  5. Clinical practice. Chronic urticaria and angioedema.
    Kaplan AP · N Engl J Med · 2002 · Background
    PubMed: PMID 11796852 · NCT00130234 · Urticaria
  6. Allergic rhinitis as a risk factor for orbital complication of acute rhinosinusitis in children.
    Holzmann D, Willi U, Nadal D, et al. · Am J Rhinol · 2002 · Background
    PubMed: PMID 11777246 · NCT00117611 · Sinusitis
  7. Basophils in chronic urticaria.
    Grattan CE · J Investig Dermatol Symp Proc · 2002 · Background
    PubMed: PMID 11764301 · NCT00130234 · Urticaria

2001 (7 papers)

  1. The kinetics of allergen-induced eotaxin level in nasal lavage fluid: its key role in eosinophil recruitment in nasal mucosa.
    Terada N, Hamano N, Kim WJ, et al. · Am J Respir Crit Care Med · 2001 · Background
    PubMed: PMID 11520718 · NCT00604786 · Rhinitis, Allergic
  2. Development of a monoclonal anti-immunoglobulin E antibody (omalizumab) for the treatment of allergic respiratory disorders.
    Schulman ES · Am J Respir Crit Care Med · 2001 · Background
    PubMed: PMID 11704611 · NCT01003301
  3. Anaphylaxis in the United States: an investigation into its epidemiology.
    Neugut AI, Ghatak AT, Miller RL, et al. · Arch Intern Med · 2001 · Background
    PubMed: PMID 11146694 · NCT00890162 · Hypersensitivity
  4. Prevalence and relationship between allergic diseases and infectious diseases.
    Chen CF, Wu KG, Hsu MC, et al. · J Microbiol Immunol Infect · 2001 · Background
    PubMed: PMID 11321129 · NCT00117611 · Sinusitis
  5. Anti-immunoglobulin E (omalizumab) therapy in seasonal allergic rhinitis.
    Casale TB · Am J Respir Crit Care Med · 2001 · Background
    PubMed: PMID 11704613 · NCT00604786 · Rhinitis, Allergic
  6. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma.
    Busse W, Corren J, Lanier BQ, et al. · J Allergy Clin Immunol · 2001 · Background
    PubMed: PMID 11496232 · NCT00117611 · Sinusitis
  7. Eotaxin-3 but not eotaxin gene expression is upregulated in asthmatics 24 hours after allergen challenge.
    Berkman N, Ohnona S, Chung FK, et al. · Am J Respir Cell Mol Biol · 2001 · Background
    PubMed: PMID 11415932 · NCT00604786 · Rhinitis, Allergic

2000 (4 papers)

  1. The incidence and correlation of allergy and chronic maxillary sinusitis.
    VAN DISHOECK HA, FRANSSEN MG · Pract Otorhinolaryngol (Basel) · 2000 · Background
    PubMed: PMID 13494297 · NCT00117611 · Sinusitis
  2. Eosinophilic gastroenteritis.
    Kelly KJ · J Pediatr Gastroenterol Nutr · 2000 · Background
    PubMed: PMID 10634296 · NCT00084097 · Hypersensitivity
  3. Chronic sinusitis.
    Hamilos DL · J Allergy Clin Immunol · 2000 · Background
    PubMed: PMID 10932063 · NCT00117611 · Sinusitis
  4. Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis.
    Adelroth E, Rak S, Haahtela T, et al. · J Allergy Clin Immunol · 2000 · Background
    PubMed: PMID 10932067 · NCT00604786 · Rhinitis, Allergic

1999 (1 paper)

  1. Down-regulation of human basophil IgE and FC epsilon RI alpha surface densities and mediator release by anti-IgE-infusions is reversible in vitro and in vivo.
    Saini SS, MacGlashan DW, Sterbinsky SA, et al. · J Immunol · 1999 · Background
    PubMed: PMID 10228046 · NCT00130234 · Urticaria

1998 (4 papers)

  1. Anti-Fc(episilon)RI auto antibodies and basophil histamine releasability in chronic idiopathic urticaria.
    Sabroe RA, Francis DM, Barr RM, et al. · J Allergy Clin Immunol · 1998 · Background
    PubMed: PMID 9802375 · NCT00130234 · Urticaria
  2. Fc epsilon receptor I on dendritic cells delivers IgE-bound multivalent antigens into a cathepsin S-dependent pathway of MHC class II presentation.
    Maurer D, Fiebiger E, Reininger B, et al. · J Immunol · 1998 · Background
    PubMed: PMID 9743330 · NCT00822783 · Dermatitis, Atopic
  3. Effect of fluticasone in severe polyposis.
    Lund VJ, Flood J, Sykes AP, et al. · Arch Otolaryngol Head Neck Surg · 1998 · Background
    PubMed: PMID 9604976 · NCT00117611 · Sinusitis
  4. Intranasal beclomethasone reduces allergen-induced symptoms and superficial mucosal eosinophilia without affecting submucosal inflammation.
    Baroody FM, Rouadi P, Driscoll PV, et al. · Am J Respir Crit Care Med · 1998 · Background
    PubMed: PMID 9517609 · NCT01003301

1997 (8 papers)

  1. Determinants of airway responses to cat allergen: comparison of environmental challenge to quantitative nasal and bronchial allergen challenge.
    Sicherer SH, Wood RA, Eggleston PA, et al. · J Allergy Clin Immunol · 1997 · Background
    PubMed: PMID 9215248 · NCT01003301
  2. Down-regulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody.
    MacGlashan DW, Bochner BS, Adelman DC, et al. · J Immunol · 1997 · Background
    PubMed: PMID 9013989 · NCT01003301
  3. Sinusitis: bench to bedside. Current findings, future directions.
    Kaliner MA, Osguthorpe JD, Fireman P, et al. · Otolaryngol Head Neck Surg · 1997 · Background
    PubMed: PMID 9212028 · NCT00117611 · Sinusitis
  4. Clinical significance of asymptomatic sinus abnormalities on magnetic resonance imaging.
    Iwabuchi Y, Hanamure Y, Ueno K, et al. · Arch Otolaryngol Head Neck Surg · 1997 · Background
    PubMed: PMID 9193220 · NCT00117611 · Sinusitis
  5. Fluticasone propionate aqueous nasal spray in the treatment of nasal polyposis.
    Holmberg K, Juliusson S, Balder B, et al. · Ann Allergy Asthma Immunol · 1997 · Background
    PubMed: PMID 9087151 · NCT00117611 · Sinusitis
  6. The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects.
    Fahy JV, Fleming HE, Wong HH, et al. · Am J Respir Crit Care Med · 1997 · Background
    PubMed: PMID 9196082 · NCT01003301
  7. Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis.
    Casale TB, Bernstein IL, Busse WW, et al. · J Allergy Clin Immunol · 1997 · Background
    PubMed: PMID 9257795 · NCT00604786 · Rhinitis, Allergic
  8. The development of the Rhinosinusitis Disability Index.
    Benninger MS, Senior BA · Arch Otolaryngol Head Neck Surg · 1997 · Background
    PubMed: PMID 9366696 · NCT00117611 · Sinusitis

1996 (4 papers)

  1. Characteristics of histamine-releasing activity in the sera of patients with chronic idiopathic urticaria.
    Zweiman B, Valenzano M, Atkins PC, et al. · J Allergy Clin Immunol · 1996 · Background
    PubMed: PMID 8765822 · NCT00130234 · Urticaria
  2. Eosinophilic gastroenteritis associated with food allergy and bronchial asthma.
    Park HS, Kim HS, Jang HJ, et al. · J Korean Med Sci · 1996 · Background
    PubMed: PMID 8527050 · NCT00084097 · Hypersensitivity
  3. Eosinophilic gastroenteritis.
    Lee M, Hodges WG, Huggins TL, et al. · South Med J · 1996 · Background
    PubMed: PMID 8578348 · NCT00084097 · Hypersensitivity
  4. Clinical characteristics and genotype analysis of patients with cystic fibrosis and nasal polyposis requiring surgery.
    Kingdom TT, Lee KC, FitzSimmons SC, et al. · Arch Otolaryngol Head Neck Surg · 1996 · Background
    PubMed: PMID 8906056 · NCT00117611 · Sinusitis

1995 (2 papers)

  1. Trends in antimicrobial drug prescribing among office-based physicians in the United States.
    McCaig LF, Hughes JM · JAMA · 1995 · Background
    PubMed: PMID 7807660 · NCT00117611 · Sinusitis
  2. The high affinity IgE receptor (Fc epsilon RI) mediates IgE-dependent allergen presentation.
    Maurer D, Ebner C, Reininger B, et al. · J Immunol · 1995 · Background
    PubMed: PMID 7759866 · NCT00822783 · Dermatitis, Atopic

1994 (2 papers)

  1. Does allergic rhinitis predispose to sinusitis?
    Karlsson G, Holmberg K · Acta Otolaryngol Suppl · 1994 · Background
    PubMed: PMID 8067239 · NCT00117611 · Sinusitis
  2. Sinusitis in allergic patients.
    Iwens P, Clement PA · Rhinology · 1994 · Background
    PubMed: PMID 7939142 · NCT00117611 · Sinusitis

1993 (1 paper)

  1. Humanization of an antibody directed against IgE.
    Presta LG, Lahr SJ, Shields RL, et al. · J Immunol · 1993 · Background
    PubMed: PMID 8360482 · NCT00604786 · Rhinitis, Allergic

1992 (1 paper)

  1. Tryptase and histamine as markers to evaluate mast cell activation during the responses to nasal challenge with allergen, cold, dry air, and hyperosmolar solutions.
    Proud D, Bailey GS, Naclerio RM, et al. · J Allergy Clin Immunol · 1992 · Background
    PubMed: PMID 1607547 · NCT00604786 · Rhinitis, Allergic

1991 (2 papers)

  1. Acute and chronic urticaria and angioedema.
    Soter NA · J Am Acad Dermatol · 1991 · Background
    PubMed: PMID 1869689 · NCT00130234 · Urticaria
  2. CT evaluation of the paranasal sinuses in symptomatic and asymptomatic populations.
    Calhoun KH, Waggenspack GA, Simpson CB, et al. · Otolaryngol Head Neck Surg · 1991 · Background
    PubMed: PMID 1903859 · NCT00117611 · Sinusitis

1990 (1 paper)

  1. Perennial nonallergic rhinitis: a retrospective review.
    Enberg RN · Ann Allergy · 1990 · Background
    PubMed: PMID 2480728 · NCT00117611 · Sinusitis

1989 (1 paper)

  1. Magnetic resonance imaging of the paranasal sinuses: frequency and type of abnormalities.
    Conner BL, Roach ES, Laster W, et al. · Ann Allergy · 1989 · Background
    PubMed: PMID 2719356 · NCT00117611 · Sinusitis

1985 (2 papers)

  1. Inflammatory mediators in late antigen-induced rhinitis.
    Naclerio RM, Proud D, Togias AG, et al. · N Engl J Med · 1985 · Background
    PubMed: PMID 2582257 · NCT00604786 · Rhinitis, Allergic
  2. Clinical findings in patients with allergic rhinitis.
    Binder E, Holopainen E, Malmberg H, et al. · Rhinology · 1985 · Background
    PubMed: PMID 6522975 · NCT00117611 · Sinusitis

1978 (1 paper)

  1. Sinus disease in children with respiratory allergy.
    Rachelefsky GS, Goldberg M, Katz RM, et al. · J Allergy Clin Immunol · 1978 · Background
    PubMed: PMID 641266 · NCT00117611 · Sinusitis

1977 (1 paper)

  1. Nasal polyps in asthma and rhinitis. A review of 6,037 patients.
    Settipane GA, Chafee FH · J Allergy Clin Immunol · 1977 · Background
    PubMed: PMID 833373 · NCT00117611 · Sinusitis

1976 (2 papers)

  1. Defective histamine release in chronic urticaria.
    Kern F, Lichtenstein LM · J Clin Invest · 1976 · Background
    PubMed: PMID 57121 · NCT00130234 · Urticaria
  2. Surgery for chronic hyperplastic rhinosinusitis.
    Friedman WH · Laryngoscope · 1976 · Background
    PubMed: PMID 1202305 · NCT00117611 · Sinusitis

Sources and methodology

This page summarizes published evidence for general reference and does not constitute medical advice. For clinical decisions, consult the linked primary publications and your healthcare provider. Data sourced from PubMed and the ClinicalTrials.gov / AACT database maintained by the Clinical Trials Transformation Initiative (CTTI).